Hyperkalemia Risk of Finerenone Versus Spironolactone in CKD patients with type 2 Diabetes

Authors

Abiodun Idowu, Department of Medicine, Jefferson Einstein Hospital, Philadelphia, PA, USA.
Kevin Bryan Lo, Department of Cardiology, Brigham and Women's Hospital, Boston, MA, USA.
Olayinka Adebolu, Department of Medicine, Jefferson Einstein Hospital, Philadelphia, PA, USA.
Michael Hamilton, Department of Medicine, Jefferson Einstein Hospital, Philadelphia, PA, USA.
Peter Abdelmaseeh, Department of Cardiology, Jefferson Einstein Hospital, Philadelphia, PA, USA.
Sankar D. Navaneethan, Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, Texas.
Janani Rangaswami, Washington DC VA Medical Center, Washington, DC, USA.

Document Type

Journal Article

Publication Date

5-29-2025

Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

DOI

10.1093/ndt/gfaf098

APA Citation

Idowu, Abiodun; Lo, Kevin Bryan; Adebolu, Olayinka; Hamilton, Michael; Abdelmaseeh, Peter; Navaneethan, Sankar D.; and Rangaswami, Janani, "Hyperkalemia Risk of Finerenone Versus Spironolactone in CKD patients with type 2 Diabetes" (2025). GW Authored Works. Paper 7196.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/7196

Department

Medicine